GeneDx Holdings Corp. (WGS)Healthcare | Diagnostics & Research | Stamford, United States | NasdaqGS
70.22 USD
+1.61
(2.347%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:32 a.m. EDT
The investment case for GeneDx is currently compromised by severe legal overhangs and deteriorating operational performance. The company faces multiple class-action lawsuit deadlines, creating a persistent cloud of litigation risk that suppresses valuation. Fundamentally, the business is struggling with negative free cash flow, negative operating margins, and a return on equity of -40%, indicating capital destruction. While the stock recently rallied significantly, the most recent price action shows a sharp correction, dropping nearly 25% in just two weeks, which aligns with the defensive positioning seen in the options chain. The lack of dividends and the heavy speculative short interest suggest the market views this as a distressed situation rather than a turnaround story. Until the legal threats are resolved and profitability is restored, the risk-reward profile remains skewed heavily against the buyer. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.273628 |
| AutoARIMA | 0.288189 |
| AutoETS | 0.288193 |
| AutoTheta | 0.288411 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 4.15 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.567 |
| Excess Kurtosis | -0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 68.545 |
| Revenue per Share | 15.551 |
| Market Cap | 2,094,138,752 |
| Forward P/E | 58.59 |
| Beta | 1.97 |
| Profit Margins | -23.41% |
| Previous Name | Mount Sinai Genomics, Inc. |
| Website | https://www.genedx.com |
As of Oct. 10, 2026, 3:32 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest, particularly at strikes below the current price (e.g., 65, 50) and deep out-of-the-money strikes (25, 30) showing massive IV spikes. Call activity is sparse and concentrated near the money or slightly out-of-the-money, while significant call open interest walls exist far above current prices (110, 120), suggesting a lack of immediate bullish conviction. The imbalance indicates a market expecting further downside volatility rather than a rebound.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4193815 |
| Address1 | North Tower |
| Address2 | 6th Floor 333 Ludlow Street |
| All Time High | 896.94 |
| All Time Low | 1.16 |
| Ask | 80.89 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 685,350 |
| Average Daily Volume3 Month | 721,703 |
| Average Volume | 721,703 |
| Average Volume10Days | 685,350 |
| Beta | 1.969 |
| Bid | 64.5 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 8.194 |
| City | Stamford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 70.22 |
| Current Ratio | 3.301 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 72.7 |
| Day Low | 66.3495 |
| Debt To Equity | 68.545 |
| Display Name | GeneDx |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,789,000 |
| Earnings Call Timestamp Start | 1,785,789,000 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,131,200 |
| Earnings Timestamp Start | 1,793,131,200 |
| Ebitda | -33,695,000 |
| Ebitda Margins | -0.074149996 |
| Enterprise To Ebitda | -63.184 |
| Enterprise To Revenue | 4.685 |
| Enterprise Value | 2,128,992,768 |
| Eps Current Year | 0.13143 |
| Eps Forward | 1.19857 |
| Eps Trailing Twelve Months | -3.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 201 421 2010 |
| Fifty Day Average | 81.8855 |
| Fifty Day Average Change | -11.665497 |
| Fifty Day Average Change Percent | -0.14246109 |
| Fifty Two Week Change Percent | -41.93815 |
| Fifty Two Week High | 170.87 |
| Fifty Two Week High Change | -100.649994 |
| Fifty Two Week High Change Percent | -0.5890443 |
| Fifty Two Week Low | 32.21 |
| Fifty Two Week Low Change | 38.010002 |
| Fifty Two Week Low Change Percent | 1.1800684 |
| Fifty Two Week Range | 32.21 - 170.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,604,500,200,000 |
| Float Shares | 20,443,352 |
| Forward Eps | 1.19857 |
| Forward P E | 58.586483 |
| Free Cashflow | -47,501,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,300 |
| Fullday Change | 3.7200012 |
| Fullday Change Percent | 5.421952 |
| Fullday Price | 70.22 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.69383 |
| Gross Profits | 315,296,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0771 |
| Held Percent Institutions | 1.0880799 |
| Implied Shares Outstanding | 29,822,541 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,683,158,400 |
| Last Split Factor | 1:33 |
| Long Business Summary | GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut. |
| Long Name | GeneDx Holdings Corp. |
| Market | us_market |
| Market Cap | 2,094,138,752 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_608642327 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -106,357,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,540,731,380 |
| Number Of Analyst Opinions | 8 |
| Open | 68.6 |
| Operating Cashflow | -48,712,000 |
| Operating Margins | -0.15211001 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 888 729 1206 |
| Prev Name | Mount Sinai Genomics, Inc. |
| Previous Close | 68.61 |
| Price Eps Current Year | 534.2768 |
| Price Hint | 2 |
| Price To Book | 8.569685 |
| Price To Sales Trailing12 Months | 4.6083164 |
| Profit Margins | -0.23405 |
| Quick Ratio | 2.896 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.125 |
| Region | US |
| Regular Market Change | 1.61 |
| Regular Market Change Percent | 2.3466 |
| Regular Market Day High | 72.7 |
| Regular Market Day Low | 66.3495 |
| Regular Market Day Range | 66.3495 - 72.7 |
| Regular Market Open | 68.6 |
| Regular Market Previous Close | 68.61 |
| Regular Market Price | 70.22 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 796,628 |
| Return On Assets | -0.0789 |
| Return On Equity | -0.408 |
| Revenue Growth | 0.114 |
| Revenue Per Share | 15.551 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 29,822,541 |
| Shares Percent Shares Out | 0.1887 |
| Shares Short | 5,626,310 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,001,270 |
| Short Name | GeneDx Holdings Corp. |
| Short Percent Of Float | 0.36110002 |
| Short Ratio | 7.71 |
| Source Interval | 15 |
| State | CT |
| Symbol | WGS |
| Target High Price | 103.0 |
| Target Low Price | 83.0 |
| Target Mean Price | 93.5 |
| Target Median Price | 92.5 |
| Total Cash | 132,548,000 |
| Total Cash Per Share | 4.445 |
| Total Debt | 167,402,000 |
| Total Revenue | 454,425,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 75.3318 |
| Two Hundred Day Average Change | -5.111801 |
| Two Hundred Day Average Change Percent | -0.067857146 |
| Type Disp | Equity |
| Volume | 796,628 |
| Website | https://www.genedx.com |
| Zip | 6,902 |